LLY - Lilly's Olumiant undergoes European review for hospitalized COVID-19 patients

The European Medicines Agency (“EMA”) has started to review a marketing application to expand the use of Olumiant (baricitinib) for COVID-19 in hospitalized patients aged more than 10 years who require supplemental oxygen.In 2009, Eli Lilly ([[LLY]] +0.6%) and Incyte ([[INCY]] -0.9%) inked a worldwide license and collaboration agreement for the treatment which is approved for adults with moderate to severe rheumatoid arthritis or atopic dermatitis (eczema).EMA said it would make a recommendation ‘as soon as possible’ after an accelerated assessment of data from two large, randomized trials involving hospitalized COVID-19 patients. The EMA opinion is expected by July assuming there is no requirement for additional data.In June 2020, Eli Lilly announced the launch of Phase 3 trial COV-BARRIER that was designed to evaluate Olumiant in hospitalized COVID-19 patients with at least one elevated marker of inflammation but not on mechanical ventilation.

For further details see:

Lilly’s Olumiant undergoes European review for hospitalized COVID-19 patients